Profile data is unavailable for this security.
About the company
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
- Revenue in DKK (TTM)6.89bn
- Net income in DKK2.44bn
- Incorporated1992
- Employees1.74k
- LocationBavarian Nordic A/SPhilip Heymans Alle 3HELLERUP 2900DenmarkDNK
- Websitehttps://www.bavarian-nordic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 4.88bn | 658.08m | 14.55bn | 5.00k | 22.15 | 1.83 | -- | 2.98 | 0.8113 | 0.8113 | 6.07 | 9.84 | 0.493 | 1.97 | 4.84 | 1,070,948.00 | 6.65 | 9.23 | 7.91 | 12.19 | 34.65 | 33.78 | 13.50 | 15.64 | 2.42 | -- | 0.0152 | 39.55 | -6.57 | 20.67 | -41.34 | 20.58 | 22.64 | 8.45 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.42bn | 591.58m | 14.63bn | 1.36k | 24.39 | 2.38 | -- | 4.27 | 0.4079 | 0.4079 | 2.35 | 4.18 | 0.3812 | 0.6322 | 3.82 | 2,765,677.00 | 6.59 | 8.38 | 8.99 | 12.03 | 41.12 | 44.95 | 17.28 | 19.72 | 1.35 | -- | 0.2644 | 23.22 | -0.1984 | 9.70 | 536.09 | 6.43 | 34.44 | -6.04 |
| Soho Global Health Tbk PT | 3.94bn | 210.52m | 14.66bn | 2.31k | 70.37 | 13.73 | 61.73 | 3.72 | 43.77 | 43.77 | 817.94 | 224.32 | 1.87 | 5.86 | 5.03 | 4,568,340,000.00 | 9.98 | 8.80 | 19.36 | 15.89 | 16.10 | 18.23 | 5.34 | 4.94 | 1.29 | -- | 0.0034 | 68.07 | 22.69 | 14.78 | 24.59 | 31.32 | 27.97 | -- |
| China Resources Jingzhng Phrmctcl Co Ltd | 4.00bn | 762.25m | 14.71bn | 4.18k | 19.24 | 4.26 | -- | 3.67 | 1.32 | 1.32 | 6.94 | 5.98 | 0.6755 | 3.53 | 11.30 | 1,051,350.00 | 14.12 | 11.45 | 23.31 | 16.72 | 60.96 | 64.04 | 20.91 | 18.23 | 1.33 | -- | 0.0348 | 93.25 | -2.59 | 12.61 | 9.67 | 11.20 | 30.67 | 36.85 |
| Bavarian Nordic A/S | 6.89bn | 2.44bn | 14.84bn | 1.74k | 6.13 | 1.11 | 4.71 | 2.15 | 30.57 | 30.57 | 85.79 | 168.13 | 0.4732 | 1.34 | 6.08 | 4,274,910.00 | 16.80 | 3.31 | 20.18 | 4.02 | 54.33 | 52.68 | 35.50 | 9.80 | 2.43 | -- | 0.0101 | 0.00 | -19.06 | 53.88 | -33.03 | -- | -8.77 | -- |
| Nippon Shinyaku Co Ltd | 6.82bn | 1.23bn | 14.88bn | 2.24k | 11.64 | 1.22 | 10.01 | 2.18 | 443.17 | 443.17 | 2,465.26 | 4,211.80 | 0.5421 | 1.17 | 3.19 | 74,028,980.00 | 9.75 | 10.89 | 10.81 | 12.74 | 67.29 | 63.93 | 17.98 | 17.67 | 4.04 | -- | 0.0089 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| Dermapharm Holding SE | 8.67bn | 866.89m | 14.88bn | 3.55k | 17.20 | 3.07 | 10.51 | 1.72 | 2.15 | 2.15 | 21.54 | 12.06 | 0.5472 | 1.13 | 9.18 | 321,361.20 | 5.39 | 7.72 | 6.40 | 9.04 | 66.57 | 63.64 | 9.85 | 11.81 | 1.04 | 4.88 | 0.61 | 52.26 | 4.00 | 11.00 | 82.44 | 8.07 | -3.81 | -- |
| Piramal Pharma Ltd | 6.15bn | -113.48m | 15.09bn | 7.13k | -- | -- | 31.43 | 2.45 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Bavarian Nordic A/S's reporting currency: Danish Krone DKK
23.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 2024 | 8.02m | 10.12% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 3.02m | 3.82% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.67m | 2.10% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.64m | 2.07% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 1.22m | 1.53% |
| Amundi Asset Management SASU (Investment Management)as of 07 Jan 2026 | 847.95k | 1.07% |
| Nykredit Bank A/S (Investment Management)as of 31 Jan 2026 | 773.48k | 0.98% |
| BI Asset Management Fondsm�glerselskab A/Sas of 30 Jan 2026 | 722.75k | 0.91% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 561.72k | 0.71% |
| Victory Capital Management, Inc. (Investment Management)as of 31 Dec 2025 | 372.91k | 0.47% |
More ▼
Data from 30 Jun 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
